Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
January 22, 2019
VOS showed statistical superiority to Restasis® on FDA-accepted objective signs of DES 42.9% of VOS subjects vs 18.4% of Restasis® subjects (p=.0055) demonstrated ≥ 10mm improvement in STT... Learn More
Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion
December 3, 2018
Trial evaluating safety and efficacy of Staccato Alprazolam in subjects with epilepsy and a predictable seizure pattern Results from the open label portion of the study will be presented at a... Learn More
Antios Therapeutics Raises $25 Million in Oversubscribed Series A Financing to Pursue Hepatitis B Cure
November 27, 2018
International Group of Investors from Canada, the U.S. and China Support Former Senior Executives from Pharmasset and Idenix in New Venture ATLANTA, Nov. 27, 2018 /PRNewswire/ -- Antios... Learn More
October 18, 2018
With Reimbursement in Place and Positive Late-Breaking Data, Company Expects Continued Growth in Germany Kirkland, Wash. – October 18, 2018 – Cardiac Dimensions, a leader in the development... Learn More
Our investment team of 9 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.
Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.
“Lumira’s philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael’s ability to accelerate the pace.”
Dr. Arthur Slutsky | Vice-President
Vice-President of Research at St. Michael’s Hospital
“Lumira’s model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation.”
Barbara Grantham | President & Ceo
VGH & UBC Hospital Foundation
“This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”
Paul Alofs | President & Ceo
Princess Margaret Cancer Foundation
Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.
141 Adelaide Street
Canada, M5H 3L5
3400 De Maisonneuve Ouest,
Canada, H3Z 3B8
1021 West Hastings Street,
Canada, V6E 0C3
303 Wyman Street